Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
Clinical trial NCT07675070 · RECRUITING
Trial details
- NCT number
- NCT07675070
- Sponsor
- NanoAlvand
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-03-22
- Primary completion
- 2026-09-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.